Co-Diagnostics (CODX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Sep, 2026Executive summary
Special Meeting called to approve three proposals: warrant exercise, reverse stock split, and adjournment authority.
Board unanimously recommends voting in favor of all proposals.
Proposals aim to support capital structure flexibility, compliance with Nasdaq, and potential future financings.
Voting matters and shareholder proposals
Proposal 1: Approve exercise of new warrants for up to 3,404,724 shares at $1.56 per share, issued August 3, 2026.
Proposal 2: Approve reverse stock split at a ratio between 1-for-2 and 1-for-50, ratio and timing at Board's discretion within 12 months.
Proposal 3: Approve adjournment or postponement of the meeting to solicit additional votes if needed.
All proposals require a majority of votes cast for approval; abstentions and broker non-votes do not affect outcomes.
No dissenters' rights are available for any proposal.
Board of directors and corporate governance
Board retains discretion on reverse stock split ratio and timing.
Directors and executive officers have no substantial interests in the proposals beyond their shareholdings.
Stockholder communications with the Board are facilitated via confidential email.
Latest events from Co-Diagnostics
- ReadyGo collaboration and automation drive blood-based testing, rapid outbreak response, and global expansion.CODX
Status update - Annual Meeting adjourned to September 24, 2026; shareholders notified of new date.CODX
Proxy filing - Registering 3.4M shares for resale; up to $5.31M in proceeds possible from warrant exercises.CODX
Registration filing - Net loss narrowed as regulatory milestones advanced and global commercialization expanded.CODX
Q2 2026 - Annual meeting covers director elections, equity plan, pay, auditor, quorum, and adjournment.CODX
Proxy filing - Proxy covers director elections, equity plan, compensation, auditor, and governance changes.CODX
Proxy filing - Resale registration for 4.94M shares enables potential $5.18M capital, but poses dilution risk.CODX
Registration filing - Q3 revenue dropped and net loss widened as diagnostics pipeline and cash reserves remained strong.CODX
Q3 2024 - Net loss narrowed to $7.5M as PCR pipeline advanced, but liquidity risks remain.CODX
Q1 2025